



COMPREHENSIVE COVERAGE INFORMATION FOR YOUR PATIENTS

Learn More About Coverage
and Reimbursement

Indication

YUPELRI[®] inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.

See full Important Safety Information on back cover.

COMPREHENSIVE COVERAGE FOR YOUR PATIENTS

For Your Patients With Medicare*

YUPELRI is covered for up to 100% of patients with Medicare Part B

- For patients with supplemental insurance (over 80% of beneficiaries), coinsurance costs can be as low as \$0*
- Medicare Part B covers most nebulizers as durable medical equipment (DME) for patient use at home^{1†}



J-CODE J7677

For Your Patients With Commercial Coverage

YUPELRI may be covered under individual insurance plans

- Commercially insured patients may be eligible to save on their out-of-pocket costs with the YUPELRI Patient Savings Card[†]
- Eligible, commercially insured patients may save up to \$550 per 30-day prescription up to 12 times per calendar year, with a max yearly savings of \$6,600



Not an actual card

Learn more at YUPELRIHCP.com

For Your Patients Who Are Uninsured

Eligible YUPELRI patients may qualify for the Mylan Patient Assistance Program[‡]

- For more information, please direct patients to email or call:

customer.service@mylan.com

1-800-796-9526

*This is not a guarantee of coverage. Site of care will determine coverage. Check with your patient's insurance provider for coverage rules and restrictions. In certain limited instances, YUPELRI may be covered through a patient's Medicare Part D pharmacy benefit.

[†]Please see full Terms and Conditions at YUPELRIHCP.com. This offer is not valid for patients covered through Medicare, Medicaid, or any other federal or state-funded healthcare program or where prohibited by law. Mylan Specialty L.P. reserves the right to amend or end this program at any time without notice. This Savings Card can be used to reduce the amount of your out-of-pocket expenses for YUPELRI up to a maximum of \$550 per 30-day prescription while this program remains in effect. No other purchase is necessary. This offer can be used up to a total of 12 times per calendar year with a savings cap of \$6,600 per calendar year while this program remains in effect. Valid prescription with Prescriber ID# is required. Mylan Specialty L.P. reserves the right to amend or end this program at any time without notice.

Eligibility Requirements: This Savings Card can be redeemed only by patients or patient guardians who are 18 years of age or older and who are residents of the United States and its territories. Patients must have commercial insurance. This program is not valid for uninsured patients (but may be used by commercially insured patients without coverage for YUPELRI) and patients who are covered by any state or federally funded healthcare program, including but not limited to any state pharmaceutical assistance program, Medicare (Part D or otherwise), Medicaid, Medigap, VA or DOD, or TriCare (regardless of whether YUPELRI is covered by such government program); not valid if the patient is Medicare-eligible and enrolled in an employer-sponsored health plan or prescription benefit program for retirees; and not valid if the patient's insurance plan is paying the entire cost of this prescription. This program is void outside the US and its territories or where prohibited by law, taxed, or restricted. Absent a change in Massachusetts law, this program will no longer be valid for Massachusetts residents after June 30, 2020. Visit: www.YUPELRI.com/copy for YUPELRI Savings Card program full Terms and Conditions.

[‡]Patients must meet financial and other program-specific criteria to be eligible for assistance.

GET YOUR MEDICARE PART B PATIENTS STARTED TODAY

Be Sure to Use the Appropriate Codes*

ICD-10 COPD Code	J-CODE
J40 - J44.9*	J7677

New patients may need 2 separate prescriptions and a detailed written order[†]

When prescribing YUPELRI for patients new to nebulized therapy, include the following:

1. A prescription for YUPELRI may look like the following:

Specify:

- Dosing instructions
- "Via nebulizer"
- Quantity to be dispensed
- Number of refills
- J-CODE J7677
- Applicable ICD-10 code: J40 - J44.9*
- Covered through the Part B Medical benefit[†]

2. A prescription for a standard jet nebulizer may look like the following (if a nebulizer is needed)[‡]:

Specify:

- Compressor
- Administration set
- Applicable ICD-10 code: J40 - J44.9*
- Covered through the Part B Medical benefit^{1†}

Rx

YUPELRI inhalation solution

175 mcg/3 mL vial

One vial QD via standard jet nebulizer

Dispense #30 vials (5,250 mcg billing units)

Refills #11

Primary diagnosis: Chronic Obstructive Pulmonary Disease

ICD-10: _____ (J40-J44.9)

Covered through the Part B Medical benefit

Rx

Standard jet nebulizer:

- Compressor E0570
- Administration set A7005
- Mouthpiece A7016

Primary diagnosis: Chronic Obstructive Pulmonary Disease

ICD-10: _____ (J40-J44.9)

Date of face-to-face evaluation: _____

Covered through the Part B Medical benefit

For example only.

3. Detailed written order²

Medicare requires a physician to document that a face-to-face encounter/examination with the patient, detailing the treatment and/or evaluation of a condition that supports the need for the nebulizer, occurred within the 6 months prior to the written order for a nebulizer.

Important Safety Information

YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta₂-agonist.

*Other codes may apply.

[†] This is not a guarantee of coverage. Site of care will determine coverage. Check with your patient's insurance provider for coverage rules and restrictions. In certain limited instances, YUPELRI may be covered through a patient's Medicare Part D pharmacy benefit.

[‡] DME suppliers may require additional documentation.



THE FIRST AND ONLY ONCE-DAILY NEBULIZED LAMA³



Proven 24-hour control³

Responses as early as 30 minutes⁴



Once-daily dosing³

Administered with any standard jet nebulizer with a mouthpiece



Up to 100% of patients with Medicare Part B are covered*

J-CODE 7677

YUPELRI was studied in two 12-week, randomized, double-blind, placebo-controlled, parallel-group confirmatory studies (studies 1 and 2) to evaluate the efficacy of once-daily YUPELRI vs placebo in patients with moderate to very severe COPD.³ The primary endpoint was change from baseline in trough (predose) FEV₁ at day 85 vs placebo: YUPELRI demonstrated a statistically significant difference vs placebo in Study 1 (146 mL, $P < .0001$ [YUPELRI, n=189; placebo, n=191]) and Study 2 (147 mL, $P < .0001$ [YUPELRI, n=181; placebo, n=187]).^{3,4}

In addition, a prespecified exploratory analysis was performed using serial spirometry on a substudy population over 24 hours on days 84/85. In study 1, LS mean changes from baseline in FEV₁ ranged from 55.8 mL to 240.4 mL in the YUPELRI group (n=45), and from -113.6 mL to 59.6 mL in the placebo group (n=44). In study 2, LS mean changes from baseline in FEV₁ ranged from 19.8 mL to 148.5 mL in the YUPELRI group (n=44), and from -176.4 mL to -13.0 mL in the placebo group (n=39).^{3,4}

An exploratory analysis of the time to achieve a 100 mL increase in FEV₁ on day 1 showed that the median (95% CI) time to achieve an increase in FEV₁ of 100 mL was 30.0 minutes (30 to 60 minutes) in Study 1.^{3,4}

Indication

YUPELRI[®] inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.

YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta₂-agonist.

As with other inhaled medicines, YUPELRI can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with YUPELRI, it should be treated immediately with an inhaled, short-acting bronchodilator. YUPELRI should be discontinued immediately and alternative therapy should be instituted.

YUPELRI should be used with caution in patients with narrow-angle glaucoma. Patients should be instructed to immediately consult their healthcare provider if they develop any signs and symptoms of acute narrow-angle glaucoma, including eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema.

Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur.

Immediate hypersensitivity reactions may occur after administration of YUPELRI. If a reaction occurs, YUPELRI should be stopped at once and alternative treatments considered.

The most common adverse reactions occurring in clinical trials at an incidence greater than or equal to 2% in the YUPELRI group, and higher than placebo, included cough, nasopharyngitis, upper respiratory infection, headache and back pain.

Coadministration of anticholinergic medicines or OATP1B1 and OATP1B3 inhibitors with YUPELRI is not recommended.

YUPELRI is not recommended in patients with any degree of hepatic impairment.

Please see accompanying Full Prescribing Information.

*This is not a guarantee of coverage. Site of care will determine coverage. Check with your patient's insurance provider for coverage rules and restrictions. In certain limited instances, YUPELRI may be covered through a patient's Medicare Part D pharmacy benefit.

References: 1. The Official U.S Government Site for Medicare. <https://www.medicare.gov/coverage/nebulizers-nebulizer-medications> Accessed June 17, 2020. 2. Centers for Medicare & Medicaid Services. *MLN Matters*. Number MM8304. <https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Medical-Review/Downloads/DetailedWrittenOrdersandFacetoFaceEncounters.pdf>. Published July 1, 2013. Accessed June 01, 2020. 3. YUPELRI [package insert]. Morgantown, WV: Mylan Specialty LP; May 2019. 4. Data on file, Mylan Specialty L.P.

The YUPELRI name and the YUPELRI logo are registered trademarks of Mylan N.V. MYLAN and the Mylan logo are registered trademarks of Mylan Inc. THERAVANCE[®] and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies.

© 2020 Mylan N.V. All rights reserved.



Learn more at [YUPELRIHCP.com](https://www.yupelrihcp.com)